| Structural highlights
Function
[AGNO_POVJC] Alters the structure of the nuclear envelope by interacting with host CBX5 and disrupting CBX5 association with LBR. Involved in the perinuclear-nuclear localization of the capsid protein VP1 during virion assembly and maturation. Plays an important role in the release of progeny virions from infected cells and in viral propagation, probably by acting as a viral ionic channel in the host plasma membrane. Allows influx of extracellular calcium ions in the host cell. May contribute to viral genome transcription and translation of viral late proteins.[1] [2] [3]
Publication Abstract from PubMed
Agnoprotein is one of the key regulatory proteins of polyomaviruses, including JCV, BKV and SV40 and is required for a productive viral life cycle. We have recently reported that agnoprotein forms stable dimer/oligomers mediated by a predicted amphipathic alpha-helix, spanning amino acids (aa), 17 to 42. Deletion of the alpha-helix renders a replication incompetent virus. Here, we have further characterized this region by a systematic deletion and substitution mutagenesis and demonstrated that a Leu/Ile/Phe-rich domain, (spanning aa 28-39) within alpha-helix is indispensable for agnoprotein structure and function. Deletion of aa 30-37 severely affects the dimer/oligomer formation and stable expression of the protein. Mutagenesis data also indicate that the residues, 34-36, may be involved in regulation of the splicing events of JCV transcripts. Collectively, these data suggest that the Leu/Ile/Phe-rich domain plays critical roles in agnoprotein function and thus represents a potential target for developing novel therapeutics against JCV infections.
Essential roles of Leu/Ile/Phe-rich domain of JC virus agnoprotein in dimer/oligomer formation, protein stability and splicing of viral transcripts.,Sami Saribas A, Abou-Gharbia M, Childers W, Sariyer IK, White MK, Safak M Virology. 2013 Aug 15;443(1):161-76. doi: 10.1016/j.virol.2013.05.003. Epub 2013 , Jun 6. PMID:23747198[4]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Okada Y, Endo S, Takahashi H, Sawa H, Umemura T, Nagashima K. Distribution and function of JCV agnoprotein. J Neurovirol. 2001 Aug;7(4):302-6. PMID:11517407
- ↑ Darbinyan A, Darbinian N, Safak M, Radhakrishnan S, Giordano A, Khalili K. Evidence for dysregulation of cell cycle by human polyomavirus, JCV, late auxiliary protein. Oncogene. 2002 Aug 15;21(36):5574-81. PMID:12165856 doi:http://dx.doi.org/10.1038/sj.onc.1205744
- ↑ Suzuki T, Orba Y, Okada Y, Sunden Y, Kimura T, Tanaka S, Nagashima K, Hall WW, Sawa H. The human polyoma JC virus agnoprotein acts as a viroporin. PLoS Pathog. 2010 Mar 12;6(3):e1000801. doi: 10.1371/journal.ppat.1000801. PMID:20300659 doi:http://dx.doi.org/10.1371/journal.ppat.1000801
- ↑ Sami Saribas A, Abou-Gharbia M, Childers W, Sariyer IK, White MK, Safak M. Essential roles of Leu/Ile/Phe-rich domain of JC virus agnoprotein in dimer/oligomer formation, protein stability and splicing of viral transcripts. Virology. 2013 Aug 15;443(1):161-76. doi: 10.1016/j.virol.2013.05.003. Epub 2013 , Jun 6. PMID:23747198 doi:http://dx.doi.org/10.1016/j.virol.2013.05.003
|
